Relevance. In connection with the overdiagnosis of active forms of herpes viral infections and, as a consequence, polypharmacy and the appointment of im-munotropic drugs for a long time and off-label, the problem of the need and sufficiency of therapy for children with recurrent diseases of the respiratory tract, occurring against the background of reactivation of herpes viral infections, is urgent. Clinical studies have shown that children with monthly acute respiratory in-fections (ARI) and active forms of herpesvirus infections (Epstein-Barr virus, cytomegalovirus) are characterized by lower levels of immunoglobulin A, interfe-ron-α and γ. Aim. Analysis of the effectiveness of therapy with the inclusion of meglumine acridone acetate in children with monthly infections of the respiratory tract in outpatient practice. Materials and methods. The study included 75 patients over the age of 4 years who came to an outpatient clinic with complaints of monthly ARI within the last 6 months and had markers of herpes viral infections. Results. It has been demonstrated that the use of meglumine acridone acetate in children with monthly respiratory infections leads to a statistically significant increase in complete clinical recovery (67.3% in the main group versus 8.7% in the comparison group) and the transition of herpes viruses into a latent state (53.8 and 13% respectively). Prescribing meglumine acridone acetate significantly reduced the proportion of patients with active human herpesvirus-6A / B and Epstein-Barr virus infections. In addition, the appointment of meglumine therapy with acridone acetate has a positive effect on the level of neutrophils after tre-atment, which is significantly higher in the main group than in the comparison group (3.52×109 and 2.09×109 cells, respectively). Conclusion. The drug meglumine acridone acetate (Cycloferon®) can be recommended for patients over 4 years of age as an etiotropic therapy for herpes vi-ral infections in children with monthly ARI.